Matthew Gline, CEO at Roivant Sciences Ltd. (ROIV), sold 42,106 shares at $3.07 ($129K) on 2022-09-23, disclosed to the SEC on 2022-09-27.
Open-market sale of $129k ROIV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.07 | 21,053 | $65K | 50.0% |
| 2 | $3.07 | 21,053 | $65K | 50.0% |
| Total | $3.07 avg | 42,106 | $129K | 100% |
| Filing → |
| ROIV | BUY | 2025-09-18 | $50K | — | Filing → |
| ROIV | SELL | 2024-09-24 | $46.8M | — | Filing → |
| ROIV | SELL | 2022-10-27 | $170K | — | Filing → |